Telegram founder agrees to register service in RussiaBusiness & Economy June 28, 16:50
St. Petersburg City Assembly votes against referendum on St. Isaac’s Cathedral issueSociety & Culture June 28, 16:43
Russia’s advanced Lider-class destroyer to get nuclear propulsion unitMilitary & Defense June 28, 16:06
Russia restarts production of engines for shipborne fighter jetsMilitary & Defense June 28, 15:54
Russian senate speaker calls for international cooperation in fight against cyber crimeRussian Politics & Diplomacy June 28, 15:46
Kremlin says ‘Petya’ ransomware attack validates Russia’s call to fight hackersRussian Politics & Diplomacy June 28, 14:51
Russian Navy may get new advanced aircraft carrierMilitary & Defense June 28, 14:39
Russia will boost military power against potential aggressors, Putin saysRussian Politics & Diplomacy June 28, 14:13
Moscow warns US against irresponsible steps in SyriaRussian Politics & Diplomacy June 28, 13:59
MOSCOW, 10 March. /TASS /. A group of scientists from Moscow universities led by Yan Ivanenkov, the head of Laboratory of Medical Chemistry and Bioinformatics at MIPT (Moscow Institute of Physics and Technology) has succeeded in synthesizing a set of novel selenohydantoins with anticancer and antioxidant activity, the MIPT press service said.
"It was found that synthesized molecules could potentially be used as anticancer agents with good selectivity index", MIPT said.
Hydantoin moiety and its derivatives can be found in many drug molecules, including nilutamide, which is used in chemotherapy for prostate cancer, and dantrolene, which helps to relax skeletal muscles and prevent cramps. Selenohydantoins are derivatives of hydantoins in which one of the oxygen atoms is replaced by selenium. It was found that drug molecules containing selenium possess anticancer activity and can be used as effective antioxidants. Selenium can be found in a number of known drug molecules, such as Ebselen - an antioxidant with a broad spectrum of therapeutic activity.
In the study, the scientists have synthesized novel selenium-containing hydantoin derivatives. The structures of the molecules obtained were confirmed by NMR (Nuclear Magnetic Resonance) spectroscopy, high resolution mass spectrometry, and X-ray analysis. The results of electrochemical studies showed that the synthesized molecules possess antioxidant activity, which means they are able to slow down the process of oxidation. They are also able to bind to receptors that protect the body from oxidation.
"We have examined the effect of selenium on the activity of the synthesized molecules. The next step is to investigate the pharmacological potential of the most active molecules in vivo and in vitro," said Yan Ivanenkov, the head of the Laboratory of Medical Chemistry and Bioinformatics, when commenting on the prospects of the research.
The results of the study highlighted the important role of selenium in the structure of hydantoin derivatives. Structural modification such as this has a significant influence on the spectrum of biological activity and properties of the molecules.
The corresponding paper has been published in the scientific journal Bioorganic & Medicinal Chemistry.